Literature DB >> 14614702

Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor.

Akiko Yokoi1, Kimberly W McCrudden, Jianzhong Huang, Eugene S Kim, Samuel Z Soffer, Jason S Frischer, Anna Serur, Tamara New, Jenny Yuan, Mahesh Mansukhani, Kathleen O'toole, Darrell J Yamashiro, Jessica J Kandel.   

Abstract

BACKGROUND: The human epidermal growth factor family (HER) members play a significant role in the mesenchymal-to-epithelial transition during renal tubulogenesis. HER misexpression has been linked also to loss of growth control, invasiveness, and promotion of angiogenesis in breast cancers and other human malignant tumors
METHODS: The authors screened Wilms' tumor samples and derived cell lines for expression of her2/neu, which was detected in both unfavorable and favorable histology tissues. Xenografts were implanted in mice using her2/neu(+) and her2/neu(-) cell lines and the effect of specific blockade tested using monoclonal anti-her2/neu antibody.
RESULTS: Blocking antibody suppressed tumor growth in her2/neu(+) but not her2/neu(-) experimental Wilms' tumor. In addition, antibody exposure resulted in suppression of tumor angiogenesis but no decrease in tumor cell proliferation in her2/neu(+) xenografts.
CONCLUSIONS: Her2/neu contributes to the growth of some Wilms' tumors, and an important mechanism of its action is promotion of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614702     DOI: 10.1016/s0022-3468(03)00562-1

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

1.  β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.

Authors:  Peter E Clark; Dina Polosukhina; Harold Love; Hernan Correa; Cheryl Coffin; Elizabeth J Perlman; Mark de Caestecker; Harold L Moses; Roy Zent
Journal:  Am J Pathol       Date:  2011-10-08       Impact factor: 4.307

2.  Association between the HER2 expression and histological differentiation in Wilms tumor.

Authors:  M Salem; Y Kinoshita; T Tajiri; R Souzaki; K Tatsuta; M Higashi; T Izaki; K Kohashi; M Tsuneyoshi; T Taguchi
Journal:  Pediatr Surg Int       Date:  2006-11       Impact factor: 1.827

3.  HER2/neu expression: a predictor for differentiation and survival in children with Wilms tumor.

Authors:  Seham M Ragab; Rehab M Samaka; Tahany M Shams
Journal:  Pathol Oncol Res       Date:  2009-07-17       Impact factor: 3.201

4.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

5.  KIT, PDGFRalpha and EGFR analysis in nephroblastoma.

Authors:  Sylvia C Wetli; Ivo Leuschner; Dieter Harms; Alex Rufle; Anja Foerster; Michel Bihl; Norbert Graf; Roikos Furtwaengler; Michael Paulussen; Jakob Briner; Charalampos Aslanidis; Gerd Schmitz; Luigi Tornillo; Michael J Mihatsch; Inti Zlobec; Elisabeth Bruder
Journal:  Virchows Arch       Date:  2008-05-14       Impact factor: 4.064

6.  PDE-constrained multispectral imaging of tissue chromophores with the equation of radiative transfer.

Authors:  Hyun Keol Kim; Molly Flexman; Darrell J Yamashiro; Jessica J Kandel; Andreas H Hielscher
Journal:  Biomed Opt Express       Date:  2010-09-08       Impact factor: 3.732

7.  Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings.

Authors:  Mashaallah Babashahi; Mitra Mehrazma; Seyed Javad Nasiri; Farid Azizi Jalilian; Mostafa Rezaei-Tavirani
Journal:  Iran J Cancer Prev       Date:  2013

8.  Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.

Authors:  Tanya M Trippett; Cynthia Herzog; James A Whitlock; Johannes Wolff; John Kuttesch; Rochelle Bagatell; Stephen P Hunger; Jessica Boklan; Amy A Smith; Robert J Arceci; Howard M Katzenstein; Christopher Harbison; Xiaofei Zhou; Haolan Lu; Christiane Langer; Martin Weber; Lia Gore
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 50.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.